Wall Street analysts forecast that Sierra Oncology Inc (NASDAQ:SRRA) will announce earnings of ($0.18) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Sierra Oncology’s earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.19). Sierra Oncology posted earnings of ($0.19) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 5.3%. The firm is expected to announce its next earnings report on Wednesday, November 14th.
On average, analysts expect that Sierra Oncology will report full-year earnings of ($0.71) per share for the current fiscal year, with EPS estimates ranging from ($0.74) to ($0.68). For the next financial year, analysts expect that the company will report earnings of ($0.74) per share, with EPS estimates ranging from ($0.75) to ($0.73). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Sierra Oncology.
Sierra Oncology (NASDAQ:SRRA) last issued its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.16) EPS for the quarter, meeting analysts’ consensus estimates of ($0.16).
Large investors have recently added to or reduced their stakes in the business. UBS Group AG bought a new position in Sierra Oncology during the 1st quarter worth approximately $111,000. Fred Alger Management Inc. bought a new position in Sierra Oncology during the 2nd quarter worth approximately $246,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Sierra Oncology by 25.5% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,950 shares of the biotechnology company’s stock worth $305,000 after buying an additional 20,950 shares during the last quarter. Algert Global LLC lifted its holdings in Sierra Oncology by 512.2% during the 2nd quarter. Algert Global LLC now owns 143,991 shares of the biotechnology company’s stock worth $426,000 after buying an additional 120,471 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Sierra Oncology by 91,592.6% during the 1st quarter. JPMorgan Chase & Co. now owns 221,896 shares of the biotechnology company’s stock worth $459,000 after buying an additional 221,654 shares during the last quarter. 64.23% of the stock is currently owned by institutional investors.
Shares of SRRA opened at $1.93 on Tuesday. Sierra Oncology has a one year low of $1.48 and a one year high of $4.09.
About Sierra Oncology
Sierra Oncology, Inc, a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer.
See Also: What is a put option?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.